[go: up one dir, main page]

FR09C0041I2 - - Google Patents

Info

Publication number
FR09C0041I2
FR09C0041I2 FR09C0041C FR09C0041C FR09C0041I2 FR 09C0041 I2 FR09C0041 I2 FR 09C0041I2 FR 09C0041 C FR09C0041 C FR 09C0041C FR 09C0041 C FR09C0041 C FR 09C0041C FR 09C0041 I2 FR09C0041 I2 FR 09C0041I2
Authority
FR
France
Prior art keywords
pain
inflammatory
chronic
analgesics
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR09C0041C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8176844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0041(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schwarz Pharma AG filed Critical Schwarz Pharma AG
Publication of FR09C0041I1 publication Critical patent/FR09C0041I1/fr
Application granted granted Critical
Publication of FR09C0041I2 publication Critical patent/FR09C0041I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR09C0041C 2001-03-20 2009-09-07 Active FR09C0041I2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01106891A EP1243262B1 (en) 2001-03-20 2001-03-20 Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
EP02727437A EP1373300B1 (en) 2001-03-20 2002-03-19 Novel use of a peptide class of compound for treating non neuropathic inflammatory pain
PCT/EP2002/003034 WO2002074784A2 (en) 2001-03-20 2002-03-19 Novel use of a peptide class of compound for treating non neuropathic inflammatory pain

Publications (2)

Publication Number Publication Date
FR09C0041I1 FR09C0041I1 (es) 2009-10-30
FR09C0041I2 true FR09C0041I2 (es) 2010-01-22

Family

ID=8176844

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0041C Active FR09C0041I2 (es) 2001-03-20 2009-09-07

Country Status (30)

Country Link
US (3) US6803481B2 (es)
EP (2) EP1243262B1 (es)
JP (1) JP4955906B2 (es)
KR (1) KR100773100B1 (es)
CN (2) CN100415225C (es)
AT (2) ATE327744T1 (es)
AU (1) AU2002257681C1 (es)
BR (1) BR0205823A (es)
CA (1) CA2419397C (es)
CY (3) CY1105533T1 (es)
CZ (1) CZ20032763A3 (es)
DE (3) DE60120104T2 (es)
DK (2) DK1243262T3 (es)
EA (1) EA007532B1 (es)
ES (2) ES2262567T3 (es)
FR (1) FR09C0041I2 (es)
HU (1) HUP0303600A3 (es)
IL (2) IL154087A0 (es)
LU (1) LU91590I2 (es)
MX (1) MXPA03008467A (es)
NL (1) NL300399I1 (es)
NO (1) NO20033629D0 (es)
NZ (1) NZ523865A (es)
PL (1) PL216213B1 (es)
PT (2) PT1243262E (es)
SI (2) SI1373300T1 (es)
SK (1) SK287539B6 (es)
UA (1) UA82645C2 (es)
WO (1) WO2002074784A2 (es)
ZA (1) ZA200300858B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2348646T3 (es) * 2000-08-25 2010-12-10 Research Corporation Technologies, Inc. Aminoacidos anticonvulsionantes para el tratamiento de la neurosis obsesivo-compulsiva.
EP1243262B1 (en) * 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
PT1243263E (pt) * 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
US7794987B2 (en) * 2003-12-02 2010-09-14 Ucb Pharma Gmbh Method for treating central neuropathic pain
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
CA2562937A1 (en) * 2004-04-16 2005-10-27 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
NZ552651A (en) * 2004-08-27 2010-07-30 Sanol Arznei Schwarz Gmbh Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
AR057643A1 (es) 2005-01-28 2007-12-12 Sanol Arznei Schwarz Gmbh Lacosamida para terapia adjunta
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
CA2652667A1 (en) * 2006-06-08 2007-12-13 Schwarz Pharma Ag Therapeutic combination for painful medical conditions
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
AU2007260207B2 (en) 2006-06-15 2012-11-08 Ucb Pharma Gmbh Pharmaceutical composition with synergistic anticonvulsant effect
EP1920780A1 (en) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
WO2011037833A2 (en) * 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
CN103561727B (zh) 2010-12-02 2018-03-27 优时比制药有限公司 每日给药1次的拉科酰胺制剂
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
GB2524689B (en) 2011-05-20 2016-01-27 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
NZ702325A (en) * 2012-05-10 2016-09-30 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2937698A1 (de) * 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4533657A (en) * 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr) * 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en) * 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5656267A (en) * 1991-08-22 1997-08-12 Sagen; Jacqueline Implantable cells that alleviate chronic pain in humans
TW217417B (es) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US5278729A (en) * 1992-04-10 1994-01-11 Magnavox Electronic Systems Company Compact rotatable electrical device
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
DE69529100T2 (de) * 1994-01-22 2003-07-17 British Biotech Pharmaceuticals Ltd., Cowley Metalloproteinaseinhibitoren
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5536853A (en) * 1994-04-11 1996-07-16 Chiron Corporation Opiate receptor ligands
MY113062A (en) * 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
MX9702487A (es) * 1994-10-05 1998-04-30 Darwin Discovery Ltd Compuestos peptidilo y su uso terapeutico como inhibidores de las metaloproteasas.
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en) 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
WO1997003677A1 (en) * 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US6114390A (en) * 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614542A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
ES2200184T7 (es) * 1996-07-24 2015-02-10 Warner-Lambert Company Llc Isobutilgaba y sus derivados para el tratamiento del dolor
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
DE69833858T2 (de) 1997-07-08 2007-02-22 Ono Pharmaceutical Co. Ltd. Aminosäurederivate
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
WO1999007413A1 (en) * 1997-08-11 1999-02-18 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
NZ504316A (en) 1997-10-31 2002-12-20 Basf Ag Pyrimidine substituted carboxylic acid derivatives which have amido side-chains useful as endothelin receptor antagonists
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
DE60037308T2 (de) 1999-09-03 2008-10-30 Actelion Pharmaceuticals Ltd. Bis-sulfonamiden
SE0001373D0 (sv) * 2000-04-13 2000-04-13 Karolinska Innovations Ab NPY Y1 receptor agonists and antagonists
DE60112766T2 (de) 2000-08-17 2006-03-30 Teva Pharmaceutical Industries Ltd. Verwendung von Derivaten der Valproinsäureamide und 2-Valproinsäureamide zur Behandlung und Prävention von Schmerzen und/oder Kopfschmerzen
ES2348646T3 (es) 2000-08-25 2010-12-10 Research Corporation Technologies, Inc. Aminoacidos anticonvulsionantes para el tratamiento de la neurosis obsesivo-compulsiva.
US7112612B2 (en) 2000-11-21 2006-09-26 Ucb S.A. N-alkylated GABA compounds, processes for their preparation and their use as medicaments
EP1243262B1 (en) * 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
PT1243263E (pt) 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
JP2004529132A (ja) 2001-03-27 2004-09-24 アクテリオン　ファマシューティカルズ　リミテッド １，２，３，４−テトラヒドロイソキノリン誘導体
PL373548A1 (en) 2001-04-26 2005-09-05 Bristol-Myers Squibb Company Control of compactability through crystallization
ITMI20011308A1 (it) * 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
EP1546134B1 (en) 2002-08-05 2007-05-02 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
CA2505361A1 (en) 2002-11-11 2004-05-27 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
EP1601691B1 (en) 2002-11-18 2008-01-16 BioProspecting NB Inc. Shrew paralytic peptide for use in neuromuscular therapy
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
AU2003298010A1 (en) * 2002-12-19 2004-07-29 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
EP1589959A2 (en) 2003-01-30 2005-11-02 Dynogen Pharmaceuticals Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
JP2006515326A (ja) 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
WO2004100871A2 (en) 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US7320675B2 (en) * 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
EP1537862A1 (en) 2003-12-02 2005-06-08 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
US7794987B2 (en) 2003-12-02 2010-09-14 Ucb Pharma Gmbh Method for treating central neuropathic pain
EP1541138A1 (en) 2003-12-05 2005-06-15 Schwarz Pharma Ag Novel use of peptide compounds for treating status epilepticus or related conditions
US20060009384A1 (en) 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
EP1579858A1 (en) 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
CA2562937A1 (en) 2004-04-16 2005-10-27 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
NZ552651A (en) * 2004-08-27 2010-07-30 Sanol Arznei Schwarz Gmbh Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (en) 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
EP1688137A1 (en) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 for add-on therapy of schizophrenia
US20060252749A1 (en) 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070048372A1 (en) 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions

Also Published As

Publication number Publication date
CY2009013I1 (el) 2012-01-25
MXPA03008467A (es) 2003-12-08
SI21170A (sl) 2003-10-31
EA007532B1 (ru) 2006-10-27
NO20033629L (no) 2003-08-15
AU2002257681B2 (en) 2007-06-07
CY1105533T1 (el) 2010-07-28
HK1058368A1 (en) 2004-05-14
AU2002257681C1 (en) 2008-02-21
EP1373300A2 (en) 2004-01-02
DK1243262T3 (da) 2006-10-02
ATE327744T1 (de) 2006-06-15
NZ523865A (en) 2004-12-24
US6803481B2 (en) 2004-10-12
PL216213B1 (pl) 2014-03-31
UA82645C2 (uk) 2008-05-12
EA200300932A1 (ru) 2004-04-29
PL362985A1 (en) 2004-11-15
AU2002257681A2 (en) 2002-10-03
NL300399I1 (en) 2009-10-01
IL154087A0 (en) 2003-07-31
SK287539B6 (sk) 2011-01-04
EP1373300B1 (en) 2009-05-20
DE60120104T2 (de) 2006-09-21
CN100415225C (zh) 2008-09-03
KR20040004369A (ko) 2004-01-13
WO2002074784A2 (en) 2002-09-26
JP4955906B2 (ja) 2012-06-20
ATE431833T1 (de) 2009-06-15
ZA200300858B (en) 2003-07-09
SI1373300T1 (sl) 2009-10-31
EP1243262A1 (en) 2002-09-25
DK1373300T3 (da) 2009-08-31
CA2419397C (en) 2009-09-15
CY2009013I2 (el) 2012-01-25
US8053476B2 (en) 2011-11-08
ES2262567T3 (es) 2006-12-01
KR100773100B1 (ko) 2007-11-02
SK12832003A3 (sk) 2004-02-03
IL154087A (en) 2010-05-17
ES2326627T3 (es) 2009-10-16
DE60232407D1 (de) 2009-07-02
JP2004524340A (ja) 2004-08-12
BR0205823A (pt) 2003-10-21
US20050085423A1 (en) 2005-04-21
US20030171300A1 (en) 2003-09-11
CY1109308T1 (el) 2012-01-25
PT1243262E (pt) 2006-10-31
DE122009000053I1 (de) 2010-05-27
EP1243262B1 (en) 2006-05-31
HUP0303600A2 (hu) 2004-03-01
CN1498103A (zh) 2004-05-19
CZ20032763A3 (cs) 2004-01-14
NO20033629D0 (no) 2003-08-15
FR09C0041I1 (es) 2009-10-30
US20070054962A1 (en) 2007-03-08
PT1373300E (pt) 2009-07-22
CN101332292A (zh) 2008-12-31
HUP0303600A3 (en) 2011-11-28
WO2002074784A3 (en) 2002-11-21
CA2419397A1 (en) 2002-09-26
CN101332292B (zh) 2012-06-20
DE60120104D1 (de) 2006-07-06
LU91590I2 (fr) 2009-10-05

Similar Documents

Publication Publication Date Title
FR09C0041I2 (es)
WO2002085342A3 (en) Use of nsaids for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
HUS1000008I1 (hu) Oldható CTLA4 molekulák alkalmazása reumatoid artritisz kezelésére
IL172773A (en) Formulations for the treatment of arthritis conditions
EA200400410A1 (ru) Комбинация нспвлс и ингибитора pde-4
BR9911137A (pt) Processo para tratamento de correntes de fluido
WO2004100890A3 (en) Rage g82s-related methods and compositions for treating inflammatory disorders
HUP0301828A3 (en) Use of apomorphine for the production of pharmaceutical compositions for treating sexual dysfunction with apomorphine at specified plasma concentration levels
NL1019899A1 (nl) Verwijdering van onzuiverheden uit koolwaterstofstromen.
GB9925016D0 (en) Binding surface
AU2003282359A1 (en) A3ar agonists for the treatment of inflammatory arthritis
WO2003093242A3 (en) Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
WO2002070457A8 (en) Inhibitor of monoamine uptake
WO2004062598A3 (en) Anti-inflammatory and anti-thrombotic compounds and their compositions
EA200401339A1 (ru) Нитрозированные имидазопиридины
FR2802196B3 (fr) Enceinte reactionnelle pour la denitrification des eaux usees
BR9913140A (pt) Derivados 2-oxo-2h-quinolina
FR2841241B1 (fr) Procede d'alkylation de composes aromatiques par le methane
FR2888519B1 (fr) Procede de traitement, par plasma, d'effluents gazeux
AU2002338849A1 (en) Pharmaceutical composition for the treatment of disorders of non-human mammals
TH66369A (th) เบนซิมิดาโซลที่มีประโยชน์ในการบำบัดความบกพร่องทางเพศ